Recombinant Human Butyrylcholinesterase/BCHE Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6137-CE

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6137-CE-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

P06276

Structure / Form

Monomer and disulfide-linked homodimers

Conjugate

Unconjugated

Applications

Enzyme Activity

View all Butyrylcholinesterase/BCHE Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human Butyrylcholinesterase/BCHE protein
Met1-Leu602, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu29

Predicted Molecular Mass

66 kDa

SDS-PAGE

90-100 kDa, reducing conditions

Activity

Measured by its ability to cleave Butyrylthiocholine.
The specific activity is >50,000 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

6137-CE
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: Butyrylcholinesterase/BCHE

Butyrylcholinesterase (BCHE) is a major acetylcholine hydrolyzing enzyme in the circulation (1). Although it is present in significant amounts in human plasma, no endogenous physiological substrate has been described for this enzyme. It can degrade a large number of ester-containing compounds besides acylcholines, including neurotoxic organophosphate esters. Thus, it plays significant pharmacological and toxicological roles. It is thought to be involved in the pathological progression of Alzheimer’s disease (AD) by depleting acetylcholine. In contrast to ACHE, it attenuates amyloid fibril formation in vitro (2). BCHE inhibitors have been used to delay symptoms of AD patients by virtue of their ability to enhance ACH availability (3). Its involvement in the cholinergic anti-inflammatory pathway connects BCHE and ACHE as possible markers of low-grade systemic inflammation observed in Type-2 diabetes, obesity, hypertension, coronary heart disease, and AD (4). BCHE can exist as monomers, dimers, or tetramers (1).

References

  1. Darvesh, S. et al. (2003) Nat. Rev. Neurosci. 4:131.
  2. Diamant, S. et al. (2006) Proc. Nat. Acad. Sci. 103:8628.
  3. Campbell, V. A. and  Gowran, A. (2007) Br. J. Pharm. 152:655.
  4. Das, U. N. (2007) Med Sci Monit. 13:RA214.

Alternate Names

Acylcholine acylhydrolase, BCHE, Butyrylcholine esterase, CHE1, Pseudocholinesterase

Entrez Gene IDs

590 (Human); 12038 (Mouse)

Gene Symbol

BCHE

UniProt

P06276

Additional Butyrylcholinesterase/BCHE Products

Product Documents for Recombinant Human Butyrylcholinesterase/BCHE Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Butyrylcholinesterase/BCHE Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.